The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries Venus Remedies has been the largest exporter of meropenem from India in the last three years Riding on the upcoming
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
Marking a major step in the global expansion strategy of Venus Remedies through its oncology products, this marketing authorisation from the largest GCC market will enable Venus Remedies to establish a strong foothold in GCC and MENA regions In a decisive step towards making its
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans Venus Remedies Limited, a leading research-based pharmaceutical company, has achieved another significant milestone by securing a Good Manufacturing Practices (GMP) certification from
